RT Journal Article
SR Electronic
T1 Association Between the Efficacy of Pembrolizumab and Low STK11/LKB1 Expression in High-PD-L1-expressing Non-small-cell Lung Cancer
JF In Vivo
JO In Vivo
FD International Institute of Anticancer Research
SP 2997
OP 3003
DO 10.21873/invivo.12131
VO 34
IS 5
A1 TSUKASA HASEGAWA
A1 NORIKO YANAGITANI
A1 HIRONORI NINOMIYA
A1 HIROAKI SAKAMOTO
A1 TAKEHIRO TOZUKA
A1 HIROSHI YOSHIDA
A1 YOSHIAKI AMINO
A1 SHINYA UEMATSU
A1 TAKAHIRO YOSHIZAWA
A1 RYO ARIYASU
A1 KEN UCHIBORI
A1 SATORU KITAZONO
A1 ATSUSHI HORIIKE
A1 MAKOTO NISHIO
YR 2020
UL http://iv.iiarjournals.org/content/34/5/2997.abstract
AB Background/Aim: STK11/LKB1 mutation has been suggested as a poorly responding candidate biomarker of the anti-programmed cell death-1 (PD-1) antibody; however, the association between STK11/LKB1 expression and the effects of anti-PD-1 antibodies is uncertain. The aim of the study was to correlate the efficacy of pembrolizumab monotherapy and STK11/LKB1 expression in untreated patients with non-small-cell lung carcinoma (NSCLC) and high PD-ligand 1 expression. Patients and Methods: From February 2017 to January 2020, we retrospectively analyzed 30 previously untreated patients with NSCLC and a tumor proportion score (TPS) ≥50% treated with pembrolizumab monotherapy. STK11/LKB1 expression in tumor tissue was evaluated by immunohistochemistry. Results: Twenty-three (76.7%) of the 30 patients were classified with low-STK11/LKB1 expression. The median progression-free survival and overall survival of patients with low-STK11/LKB1 expression was shorter than those with high-STK11/LKB1 expression, although the results were not statistically significant. The disease progression rate for the low-STK11/LKB1 group was higher than that of the high-STK11/LKB1 group. Conclusion: STK11/LKB1 expression, as measured by immunohistochemistry, could be a useful biomarker associated with the efficacy of pembrolizumab monotherapy for patients with NSCLC and a TPS ≥50%.